Email Updates

Search form

You are here


Oral tenofovir-based PrEP works. Faster, smarter rollout must be a top priority.

Recent clinical trials have shown clearly that daily, oral pre-exposure prophylaxis (PrEP) using the antiretroviral drugs tenofovir and emtricitabine dramatically reduces the risk of HIV infection for men and women who take it as directed. While PrEP won’t be right for every individual at risk for HIV, untold numbers of men and women will benefit – if they can access this potentially life-saving option.

So far, PrEP’s implementation has been piecemeal and incomplete. The pace and demand are picking up in the United States. In other countries, including some where the research took place, there is limited or no access. For maximum impact, PrEP rollout needs a coherent, global strategy involving many real-world demonstration projects, other research, and guidance from global health agencies. At the same time, research into new PrEP formulations—such as intermittent use of pills, or quarterly injections—could help improve adherence and achieve PrEP’s full potential.

What We're Reading

HIV activists warned that the era of AIDS denialism was returning in response to the AIDS Healthcare Foundation's opposition to PrEP at the recent SA AIDS Conference in Durban and elsewhere. Activists argue "the Foundation has consistently opposed Truvada using faulty science and fear mongering".

June 11, 2015
Times Live

The New Zealand AIDS Foundation has been given the go-ahead from Pharmac and the Ministry of Health to trial PrEP in New Zealand.

June 11, 2015
Gay NZ
Subscribe to RSS - PrEP